Induction of murine interleukin-1 beta expression by water-soluble components from Hericium erinaceum

Acta Pharmacologica Sinica

Volumn 27, Issue 8, 2006, Pages 1058-1064

  Son, Chang Gue ^a   Shin, Jang Woo ^a   Cho, Jung Hyo ^a   Cho, Chong Kwan ^a   Yun, Cheol Heui ^b   Han, Seung Hyun ^b,c  

^a Daejeon University   (South Korea)

^b Seoul National University   (South Korea)

^c International Vaccine Institute   (South Korea)

Author keywords

Hericium erinaceum; Interleukin 1; Lipopolysaccharide

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; CCAAT ENHANCER BINDING PROTEIN DELTA; CHLORAMPHENICOL ACETYLTRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HERICIUM ERINACEUM EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; PLANT EXTRACT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOASSAY; CELL LINE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EDIBLE MUSHROOM; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC TRANSCRIPTION; HERICIUM ERINACEUM; MACROPHAGE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SOLUBILITY; WESTERN BLOTTING;

AGARICALES; ANIMALS; BETA-GLUCANS; BIOLOGICAL PRODUCTS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-1BETA; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C3H; NF-KAPPA B; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1;

EID: 33746460795     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00321.x     Document Type: Article

References (43)

1. Zaidman BZ, Yassin M, Mahajna J, Wasser SP. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 2005; 67: 453-68.
2. Carrizo ME, Capaldi S, Perduca M, Irazoqui FJ, Nores GA, Monaco HL. The antineoplastic lectin of the common edible mushroom (Agaricus bisporus) has two binding sites, each specific for a different configuration at a single epimeric hydroxyl. J Biol Chem 2005; 280: 10614-23.
3. deVere White RW, Hackman RM, Soares SE, Beckett LA, Sun B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology 2002; 60: 640-4.
4. Chang R. Functional properties of edible mushrooms. Nutr Rev 1996; 54: S91-3.
5. Ko HG, Park SH, Kim SH, Park HG, Park WM. Detection and recovery of hydrolytic enzymes from spent compost of four mushroom species. Folia Microbiol (Praha) 2005; 50: 103-6.
6. Wang HX, Ng TB. A new laccase from dried fruiting bodies of the monkey head mushroom Hericium erinaceum. Biochem Biophys Res Commun 2004; 322: 17-21.
7. Kawagishi H, Mori H, Uno A, Kimura A, Chiba S. A sialic acid-binding lectin from the mushroom Hericium erinaceum. FEBS Lett 1994; 340: 56-8.
8. Nakatsugawa M, Takahashi H, Takezawa C, Nakajima K, Harada K, Sugawara Y, et al. Hericium erinaceum (yamabushitake) extract-induced acute respiratory distress syndrome monitored by serum surfactant proteins. Intern Med 2003; 42: 1219-22.
9. Lee EW, Shizuki K, Hosokawa S, Suzuki M, Suganuma H, Inakuma T, et al. Two novel diterpenoids, erinacines H and I from the mycelia of Hericium erinaceum. Biosci Biotechnol Biochem 2000; 64: 2402-5.
10. Kenmoku H, Shimai T, Toyomasu T, Kato N, Sassa T. Erinacine Q, a new erinacine from Hericium erinaceum, and its biosynthetic route to erinacine C in the basidiomycete. Biosci Biotechnol Biochem 2002; 66: 571-5.
11. Mizuno T, Wasa T, Ito H, Suzuki C, Ukai N. Antitumor-active polysaccharides isolated from the fruiting body of Hericium erinaceum, an edible and medicinal mushroom called yamabushitake or houtou. Biosci Biotechnol Biochem 1992; 56: 347-8.
12. Rossi B. IL-1 transduction signals. Eur Cytokine Netw 1993; 4: 181-7.
13. Dayer JM. Evidence for the biological modulation of IL-1 activity: the role of IL-1Ra. Clin Exp Rheumatol 2002; 20: S14-20.
14. Khoruts A, Osness RE, Jenkins MK. IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands. Eur J Immunol 2004; 34: 1085-90.
15. Wesa A, Galy A. Increased production of pro-inflammatory cytokines and enhanced T cell responses after activation of human dendritic cells with IL-1 and CD40 ligand. BMC Immunol 2002; 3: 14.
16. Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol 2001; 167: 90-7.
17. Chelvarajan RL, Gilbert NL, Bondada S. Neonatal murine B lymphocytes respond to polysaccharide antigens in the presence of IL-1 and IL-6. J Immunol 1998; 161: 3315-24.
18. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002; 20: S1-13.
19. Calkins CM, Bensard DD, Shames BD, Pulido EJ, Abraham E, Fernandez N, et al. IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia. J Endotoxin Res 2002; 8: 59-67.
20. Yamada T, Fujieda S, Yanagi S, Yamamura H, Inatome R, Yamamoto H, et al. IL-1 induced chemokine production through the association of Syk with TNF receptor-associated factor-6 in nasal fibroblast lines. J Immunol 2001; 167: 283-8.
21. Furutani Y. Molecular studies on interleukin-1 alpha. Eur Cytokine Netw 1994; 5: 533-8.
22. Uhing RJ, Adams DO. Molecular events in the activation of murine macrophages. Agents Actions 1989; 26: 9-14.
23. Gao B, Tsan MF. Induction of cytokines by heat shock proteins and endotoxin in murine macrophages. Biochem Biophys Res Commun 2004; 317: 1149-54.
24. Schilling D, Beissert T, Fenton MJ, Nixdorff K. Negative regulation of IL-1beta production at the level of transcription in macrophages stimulated with LPS. Cytokine 2001; 16: 51-61.
25. Kang JS, Jeon YJ, Suh J, Park SK, Yang KH, Kim HM. 2-Acetylaminofluorene inhibits interleukin-1beta production in LPS-stimulated macrophages by blocking NF-kappaB/Rel activation. Cancer Lett 2004; 203: 91-8.
26. Goto M, Katayama KI, Shirakawa F, Tanaka I. Involvement of NF-kappaB p50/p65 heterodimer in activation of the human pro-interleukin-1beta gene at two subregions of the upstream enhancer element. Cytokine 1999; 11: 16-28.
27. Muller JM, Ziegler-Heitbrock HW, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 1993; 187: 233-56.
28. Yang H, Tuzun E, Alagappan D, Yu X, Scott BG, Ischenko A, et al. IL-1 Receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J Immunol 2005; 175: 2018-25.
29. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-9.
30. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
31. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 2004; 3: 330-9.
32. Association of Official Analytical Chemists. 15th ed. Washington, DC: Official Methods of Analysis; 1990.
33. Jeon YJ, Man SH, Lee YW, Lee M, Yang KH, Kim HM. Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation. Immunopharmacology 2000; 48: 173-83.
34. Han SH, Yea SS, Jeon YJ, Yang KH, Kaminski NE. Transforming growth factor-beta 1 (TGF-beta1) promotes IL-2 mRNA expression through the up-regulation of NF-kappaB, AP-1 and NF-AT in EL4 cells. J Pharmacol Exp Ther 1998; 287: 1105-12.
35. Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 1982; 2: 1044-51.
36. Hsieh TC, Chiao JW. Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist. Cancer Lett 1995; 95: 119-23.
37. Kilian PL, Kaffka KL, Biondi DA, Lipman JM, Benjamin WR, Feldman D, et al. Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH: OVCAR-3). Cancer Res 1991; 51: 1823-8.
38. Paciotti GF, Tamarkin L. Interleukin-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro. Mol Endocrinol 1988; 2: 459-64.
39. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000; 12: 85-98.
40. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-79.
41. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994; 10: 405-55.
42. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80-8.
43. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol 2001; 166: 3873-81.